Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
More Growth Ahead For Farxiga From First-In-Class Kidney Disease Approval
Closing Down Jardiance’s Lead
May 04 2021
•
By
Andrew McConaghie
Farxiga has emerged as the company's star performer in its cardiovascular, renal and metabolism franchise. • Source: Alamy
More from Business
More from Scrip